The Auckland City Hospital's experience with novel H1N1 influenza in pregnant women
We have read Prof Powrie's excellent summary and wish to share our clinical experience with pregnant women with novel H1N1 influenza. 1 In the 2009 Antipodean winter, the novel H1N1 influenza pandemic was associated with a marked increase in pregnant women presenting with influenza-like illnesses (ILI). In Auckland, 46 pregnant women were diagnosed with novel H1N1 influenza. Thirty-eight women presented to one of the four public hospitals in Auckland. Four women needed intensive care (ICU) management, and two women died ( Figure 1 ).
Half the women (n ¼ 13/26) presenting to our hospital were of Maori and Pacific Island ethnicity, and were in their third trimester. Almost 70% of the women were overweight and 5/26 were morbidly obese. Diabetes was the most common medical co-morbidity (n ¼ 4). Asthma (n ¼ 2) and previous lung pathology (n ¼ 3) did not feature prominently in our cohort. Nicotine use was common (current smokers n ¼ 5, recent ex-smokers n ¼ 3).
A temperature !388C at presentation was not a sensitive screen and present in only 23%. Lymphopenia was present in 74% and 93% had raised C-reactive protein (CRP) !20 mg/L. Chest X-ray (CXR) demonstrating patchy, often bilateral, consolidation was present in 59% of our women at presentation and correlated with severity of illness.
The standard of care included oseltamivir 75 mg twice daily and oral antibiotic of clinician's choice (usually amoxycillinclavulanic acid) for five days, pending confirmation of novel H1N1 infection on nasopharyngeal swabs. If the women were unwell enough to require an inpatient admission, an intravenous antibiotic (usually cefuroxime) was used.
All pregnant women with ILI were isolated at presentation. Medical staff were expected to undertake full isolation precautions to avoid transmission among other pregnant women. If required the women were admitted to a medical ward with daily obstetric review. Number of visitors were limited. At maternity outpatient's clinics, women were screened and Figure 1 Distribution of pregnant women with novel H1N1 influenza across Auckland given respiratory masks if symptomatic of an ILI. These strict isolation procedures were put in place because the threat of novel H1N1influenza to pregnant women at that time was undefined. Historically, pregnant women are more vulnerable, and maternal morbidity and mortality in pandemics is usually higher than the average population. 2 -4 The characteristics of the four women who required ICU support were compared against the other pregnant women ( Table 1 ). The most striking feature was that these women were much heavier with a median body mass index of 40.2 kg/m 2 . The higher CRP, lower oxygen saturations and more florid CXR changes on presentation could reflect a more prolonged untreated disease course (median of nine days before receiving oseltamivir). Of this group, two women died. The autopsy of one woman revealed that death was due to severe bilateral viral pneumonia.
Three women were delivered at the time of presentation because of severe maternal hypoxia from severe infection. None of the neonates were infected and all survived. There were two early miscarriages.
Based on our experience, we would recommend that any pregnant woman presenting with an ILI should be assessed promptly with full isolation precautions. A CXR and full blood count should be part of the routine assessment. Obese women in their third trimester, who have patchy consolidation present on CXR, should be admitted for observation. We agree that oseltamivir should be started, even prior to laboratory confirmation of infection. 1, 5 Special consideration for pregnant women in influenza pandemic planning should include provisions for isolation of the unwell woman and their family members from other pregnant women. Influenza vaccination should be offered to all women who are pregnant or planning pregnancy. 6 
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